Clinical Microbiomics adds metabolomics to its portfolio with acquisition of MS-Omics to form the leading multi-omics provider for the microbiome field.
Copenhagen, October 17, 2022 – Clinical Microbiomics, a pioneering microbiome research company, today announced its acquisition of MS-Omics, a leading metabolomics provider based in Denmark.
Clinical Microbiomics is particularly known for its pioneering work on clonal-level microbiome profiling that is recognized as the most sensitive, precise, and comprehensive in the field.
With this acquisition, Clinical Microbiomics adds leading expertise in metabolite profiling from MS-Omics to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease.
Anders Grøn, CEO at Clinical Microbiomics, commented: "There is an unmet need in the microbiome field for better solutions to integrate microbiome and metabolome data. This demands a truly interdisciplinary approach – one that is made possible through this acquisition. We’re excited to engage with our network of researchers around the world to bring the new platform and services to work.”
Why is this important?
Microbiome science is widely proposed as the next frontier in addressing our most urgent health challenges and organizations worldwide are exploring this potential by developing nutritional products, live-biotherapeutics, and diagnostic tests.
The microbiome impacts health via the metabolites that it produces or modifies. This includes secondary microbial metabolites, conversion of food and drugs, and human-derived metabolites such as bile acids. In fact, the microbiome is a major source of variation in the human metabolome.
This interplay is too complex to understand from the microbiome functional potential or the metabolome alone. Clinical Microbiomics is utilizing advanced bioinformatics and systems biology to integrate the two disciplines paving the way for new innovations.
Morten Danielsen, CEO at MS-Omics, commented: “This transaction is a big milestone for our companies. It is a result of a strategic dialogue where it became clear that together we would be uniquely positioned to address microbiome research questions across the field. Together, we will be in position to offer a differentiated portfolio of services, lead the way with innovative concepts designed specifically for the fast-growing microbiome field, and benefit from improved sales coverage around the world”
Earlier this month, Clinical Microbiomics announced the finalization of a EUR 10 million investment from Seventure Partners’ “Health for Life Capital™ II” fund.
Since its foundation in 2015, Clinical Microbiomics has been innovating at the forefront of microbiome science. The company is working with the world’s leading academic institutions and microbiome innovators across food, nutrition, and consumer health companies.
Importantly Clinical Microbiomics hosts the richest data-warehouse on the market with 30k+ samples linking 3M+ bacterial strains to clinical phenotypes and is offering GCP-compliant microbiome research services for clinical trials in the pharmaceutical industry.
About Clinical Microbiomics
Our inner ecology – that delicate microbial ecosystem known as the microbiome – is the new frontier in human health. At Clinical Microbiomics, we exist to untangle its complexity in search of mechanisms that impact health and disease.
Identifying and understanding those mechanisms is like looking for a needle in a haystack and demands a truly interdisciplinary approach to microbiome science. Innovating at the forefront of the field, our team of leading scientists creates breakthrough bioinformatics tools and analytical concepts that set new standards for understanding and influencing the microbiome.
Clinical Microbiomics is proud to partner with researchers from the world’s most prominent academic institutions and leading biotech, consumer health and pharma companies. Operating as an extension of their research organizations, we work broader, analyze deeper, and connect the dots to help find the answers needed to impact health and disease.
MS-Omics ApS was founded in 2014 by Morten Danielsen and Lea G. Johnsen and is a service provider of metabolite profiling and data processing. The company has since 2014 grown rapidly and is now a leading provider of metabolomics.
MS-Omics has customers and collaboration partners in the US and most European countries. The customers are from the food, biotech, and pharma industries as well as from a diverse array of life science university groups. MS-Omics offers both GC-MS and LC-MS/MS methods for metabolite profiling and has expertise in data processing of the complex data from these instruments.
At present, the company employs twelve employees – soon fourteen. The company resides in Trørød, north of Copenhagen, and consists of two buildings with offices and laboratories housing state-of-the-art instruments.